Therapy Type: Immunotherapy (passive) (timeline)
Target Type: Unknown
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 1)
Company: Eli Lilly & Co.
Lilly has not disclosed the mechanism of action of this investigational therapeutic, nor published preclinical information about it. The drug's delivery mode indicates it is a biologic.
In April 2016, Lilly started a first-in-human trial of LY3303560 in what is to be 90 people. Healthy volunteers, or people with MCI due to AD or mild to moderate AD ascertained with a positive amyloid PET scan, are both eligible. This study evaluates a single, escalating intravenous infusion or subcutaneous injection of LY3303560 or placebo. It measures adverse effects up to 85 days after this single dose, as well as exposure and maximal achieve drug concentration in both serum and CSF. This study requires a four-day stay in a clinical research unit and 10 follow-up visits. It is being conducted in California and Maryland.
For all trials, see clinicaltrials.gov.
No Available Further Reading